Work

Changes in the 31P-NMR spectra of cats receiving lithium chloride systemically

Year: 1986

Type: article

Abstract: From the Department of Biochemistry and Biophysics. School of Medicine, University of Pennsylvania, Philadelphia. PA. P. R. is supported by NIH Medical Scientist Training Grant 5-T3?GM-07170. This work was also supported by the Ben Franklin P~~rship’s Advanced Technology Center of S.E. Pennsylvania (University City Science Center). Address reprint requests to Dr. Perry F. Renshaw, Department of Biochemistry and Biophysics. School of Medicine. University of Pennsylvania, Philadelphia, PA 19 104 Received August 19. 1985: revised December 2. 19X5 hibition of the enzyme myo-inositoli-phosphatase (Hallcher and Sherman 19801. Lithium inhibits this enzyme with a K, of 0.8 mM in vitro, which is comparable to the therapeutic serum lithium level of 0.X-l .S mM. As a result of this inhibition, systemic administration of’ lithium chloride can significantly lower myoinositol and raise myo-inos~t~~lI -phosphate (It P) levels in rat cerebral cortex (Sherman ct al. 19X I, 1985). As much as a 40-fold increase has been reported after administration of lithium chloride. As a therapeutic drug. lithium is administered chronically with a relatively low maintenance dose (approximately 0.5 meqikgiday). Thus, any attempt to explain lithium’s mechanism of ac.

Source: Biological Psychiatry

DOI: 10.1016/0006-3223(86)90133-2

Authors: Perry F. Renshaw, James J. Summers, Carl E. Renshaw, Kirk G. Hines, John S. Leigh

Institution: University of Pennsylvania

Language: English

Topic: Bipolar Disorder and Treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,489